Global pharmaceutical major Glenmark Pharmaceuticals Ltd has launched thiazolidinedione lobeglitazone for the first time in India for the treatment of type 2 diabetes in adults.
It is released under the brand name LOPG. It contains lobeglitazone (0.5 mg) and should be taken once daily under the prescription of a physician to improve glycemic control in diabetic patients. LOPG may be a therapeutic option in the management of uncontrolled type 2 diabetes among insulin-resistant diabetics. The cost of one pill is approximately Rs.10
Glenmark previously received approval from India’s drug regulator, the Drug Controller General of India, to manufacture and market lobeglitazone based on a randomized, double-blind Phase 3 clinical trial in adult type 2 diabetes patients aged 18 years and above. Lobeglitazone has shown faster and improved glycemic control at the end of this trial.
Speaking at the launch, Alok Malik, EVP and Business Head, Formulations India, Glenmark Pharmaceuticals said, “According to the International Diabetes Federation, 74 million adults in India are suffering from diabetes and 40 percent of them are insulin resistant. As India’s leading solutions provider for diabetes care, we are proud to introduce LOPG. It will be an innovative and affordable drug to help overcome insulin resistance among patients with uncontrolled type 2 diabetes in the country,” he said.